Global Basaglar Sales Track Towards $1bn Per Year

Global sales of Eli Lilly's Basaglar insulin glargine hybrid are on track to surpass $1bn per year

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business